Altamira Therapeutics Ltd

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in RNA therapeutics, allergy and viral infections, and inner ear disorders. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”. Altamira Therapeutics is developing OligoPhore™ / SemaPhore™ as a versatile platform for safe and effective delivery of nucleic acid payloads such as siRNA (small interfering ribonucleic acid), mRNA (messenger ribonucleic acid) into target cells, using systemic or local administration.

Extrahepatic delivery of therapeutic nucleic acids
RNA-based therapies are currently one of the most promising fields in medical research. However, effective and robust nucleic acid delivery remains the key rate-limiting step for unlocking the full potential of RNA therapeutics. Our OligoPhore™ / SemaPhore™ technology is a highly versatile platform that allows for effective and safe delivery of nucleic acids into cells, notably into non-liver tissues, using systemic or local administration.

Protection against airborne viruses and allergens
The nasal mucosa is the body’s first line of defense against airborne viruses or allergens as it functions as a barrier and helps to clear such particles from the nose. Our drug-free nasal spray technology reinforces these mucosal defenses by forming a thin protective film on the mucosa, trapping particles and moisturizing the mucosa through physical effects, providing natural protection.

Therapeutics against inner ear disorders
Inner ear disorders remain an important “white spot” in medicine. We are targeting histamine receptors to improve and accelerate vestibular compensation in case of acute vertigo, NMDA receptors to attenuate or suppress tinnitus (ringing in the ears) and block JNK, a key signaling pathway, to prevent stress injured sensory cells from dying and prevent acute inner ear hearing loss from becoming permanent.